摘要
目的比较阿托伐他汀与瑞舒伐他汀对冠心病PCI术后患者颈动脉内中膜厚度（CIMT）的影响。方法选取冠心病PCI术后合并颈动脉内中膜增厚患者142例，采用数字表法随机分为阿托伐他汀组71例和瑞舒伐他汀组71例，阿托伐他汀组给予阿托伐他汀20mg口服，每天1次；瑞舒伐他汀组给予瑞舒伐他汀10mg口服，每天1次。观察两组治疗6个月前后低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL—C）、CIMT变化。结果治疗6个月后，阿托伐他汀组LDL—C、CIMT均较治疗前明显降低[（3．37士1．20）mmol／L与（2．0±0．29）mmol／L、（1．29±0．06）mm与（0．91±0．23）mm]，治疗前后差异均有统计学意义（t=4．036、3．523，均P〈0．05）；瑞舒伐他汀组LDL-C、CIMT均较治疗前明显降低[（3．38±1．21）mmol／L与（1．8±0．15）mmol／L、（1．30±0.16）mnl与（0．81±0．15）mm]，治疗前后差异均有统计学意义（t=4．700、3．892，均P〈0．05）。瑞舒伐他汀组LDL—C、CIMT降低程度明显高于阿托伐他汀组，两组比较差异均有统计学意义（t=3．668、3．002，P〈0．05）。治疗6个月后，阿托伐他汀组HDL—C均较治疗前明显升高[（1．01±0．36）mmol／L与（1．10±0．31）mmo／／L]，治疗前后比较有统计学意义（t=3．801，P〈0．05）；瑞舒伐他汀组HDL，G均较治疗前明显升高[（1．03±0．32）mmol／L与（1．15±0．35）mmol／L]，治疗前后比较有统计学意义（t=3．722，P〈0．05）；瑞舒伐他汀组HDL—C升高程度明显高于阿托伐他汀组，两组差异有统计学意义（t=3．568，P〈0．05）。结论瑞舒伐他汀逆转动脉粥样硬化进程优于阿托伐他汀。
Objective To discuss the influence of atorvastatin and rosuvastatin on carotid intima - media thickness（CIMT） of patients after percutaneous coronary intervention （PCI）. Methods 142 patients after PCI with CIMT increasing were randomly divided into Lipitor group （n = 71 ） and Crest group （n = 71 ）. The Lipitor group was given atorvastatin（20mg） orally once a day. The Crest group was given rosuvastatin （20mg） orally once a day. The changes of low density lipoprotein, high density lipoprotein, liver function and CIMT before and after 12 weeks treat- ment were observed in two groups. Results After treatment for 6 months, the levels of LDL - C, CIMT in Lipitor group were lower than before treatment with statistical difference [ （3.37 ±1.20） mmol/L vs （ 2.0 ＋ 0.29 ） mmol/L, （29 ± 0.06） mm vs （0.91± 0.23 ） mm ] （ t - 4. 032,3. 523, all P 〈 0. 05 ） ; the levels of LDL - C, CIMT in Crest group were lower than before treatment with statistical difference[ （3.38 ＋ 1.21 ）mmol/L vs （1.8±0.15 ）mmol/L, （ 1.30±0.16） mm vs （0.81±0. 15 ） mm ] （ t = 4,700,3. 892, all P 〈 0.05 ）. The decreasing degree of LDL - C, CIMT was significantly lower in Crest group than that in Lipitor group with statistical difference （ t = 3. 668,3. 002, all P 〈 0.05 ）. The level of HDL - C in Lipitor group was higher than before treatment with statistical difference [ （ 1.01±0. 36） mmol/L vs （ 1.10±0.31 ） mmol/L ] （ t = 3. 801, P 〈 0.05 ）. The level of HDL - C in Crest group was higher than before treatment with statistical difference [ （ 1.03±0.32 ） mmol/L vs （ 1. 15 ±0. 35 ） mmol/L ] （ t = 3. 722 ,P 〈 0.05 ）. The decrease degree of HDL - C was significantly higher in Crest group than that in Lipitor group with statistical difference（t = 3. 568 ,P 〈 0.05）. Conclusion Rosuvastatin has better effect than atorvastatin on the reversal of atheroselerosis process.
出处
《中国基层医药》
CAS
2016年第6期884-886,共3页
Chinese Journal of Primary Medicine and Pharmacy
